Difference between revisions of "Fruquintinib (Elunate)"
Jump to navigation
Jump to search
m (Jwarner moved page Fruquintinib (HMPL-013) to Fruquintinib (Elunate): brand name) |
|||
Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Colorectal cancer]]=== | ===[[Colorectal cancer]]=== | ||
− | |||
− | |||
==History of changes in NMPA indication== | ==History of changes in NMPA indication== |
Revision as of 00:25, 4 November 2023
Mechanism of action
VEGFR inhibitor
Preliminary data
Colorectal cancer
History of changes in NMPA indication
- 2018-09: Approved for the treatment of patients with metastatic colorectal cancer (“CRC”) who have been previously treated with fluoropyrimidine, oxaliplatin and irinotecan, including those who have previously received anti-VEGF therapy and/or anti-epidermal growth factor receptor (EGFR) therapy (RAS wild type). (Based on FRESCO)
Also known as
- Code name: HMPL-013
- Brand name: Elunate